Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...

Myasthenia Gravis: Overview and Treatment

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...

Myasthenia Gravis: Diagnostic Tests

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...

Pulmonary Tuberculosis II

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...

Pulmonary Tuberculosis III

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Navigation-assisted surgery using an image-guided platform improves margin control and survival in advanced oral squamous cell carcinoma.

International journal of oral and maxillofacial surgery·2026

Same author

Performance of the Asia-Pacific Colorectal Screening score in stratifying the risk of advanced colorectal neoplasia: Some issues to be addressed.

Journal of gastroenterology and hepatology·2024

Same author

Influence of recombinant human B-type natriuretic peptide on improving ventricular function in patients with ST elevation myocardial infarction.

European review for medical and pharmacological sciences·2023

Same author

Associations of a family history of lupus with the risks of lupus and major psychiatric disorders in first-degree relatives.

QJM : monthly journal of the Association of Physicians·2022

Same author

Using transvaginal ultrasonography and MRI to evaluate ovarian volume and follicle count of infertile women: a comparative study.

Clinical radiology·2022

Same author

Does endoplasmic reticulum stress stimulate the apoptosis of granulosa cells in polycystic ovary syndrome?

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2022

Search research articles

Related Experiment Videos

Tuberculosis in myasthenia gravis.

S-M Ou¹, C-J Liu, Y-S Chang

¹Division of Nephrology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.

The International Journal of Tuberculosis and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease

|December 13, 2012

Summary

This summary is machine-generated.

Patients with myasthenia gravis (MG) have a significantly higher risk of developing tuberculosis (TB), particularly pulmonary TB. Early screening for TB is recommended for high-risk MG patients.

Related Experiment Videos

Area of Science:

Infectious Diseases
Neurology
Public Health

Background:

The association between myasthenia gravis (MG) and tuberculosis (TB) remains underexplored.
Understanding this relationship is crucial for patient management and public health strategies.

Purpose of the Study:

To investigate the potential link between myasthenia gravis and the incidence of tuberculosis.
To identify risk factors for TB development in MG patients and assess survival outcomes.

Main Methods:

A nationwide cohort study in Taiwan (2000-2006) involving 2317 MG patients.
Comparison of TB incidence rates between MG patients and matched controls using insurance database records.
Analysis of risk factors and survival rates in MG patients who developed TB.

Main Results:

MG patients exhibited a significantly higher risk of TB (aHR 1.96), predominantly pulmonary TB (aHR 2.10).
Advanced age (≥60 years) and corticosteroid use were identified as key risk factors for TB in the MG cohort.
MG patients who contracted TB had a reduced 5-year survival rate compared to those without TB (89.4% vs. 96.0%).

Conclusions:

There is a significantly elevated incidence of pulmonary TB among individuals with myasthenia gravis.
Implementing targeted TB screening protocols for high-risk myasthenia gravis patients is warranted.